New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2013
15:18 EDTCELGCelgene volatility flat as shares at record high
Celgene May option implied volatility is at 25, July is at 26; below its 26-week average of 27 according to Track Data suggesting non-directional price movement into a PDUFA Date for Revlimid on June 5.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
07:36 EDTCELGCelgene names Alles, Fouse to board of directors
Subscribe for More Information
February 10, 2016
06:33 EDTCELGCelgene expands use of Medidata's cloud platform
Subscribe for More Information
February 7, 2016
20:36 EDTCELGOn The Fly: Top five weekend stock stories
Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Ford (F) plans to build a new assembly plant in Mexico and expand its existing factory near Mexico City, sharply increasing production capacity in the country as it looks to focus its U.S. efforts on trucks and SUVs, the Wall Street Journal reported. 2. GoPro (GPRO) and Microsoft (MSFT) signed a patent licensing agreement late Friday, lifting shares of the action camera maker in after-hours trading. 3. Media reports indicate Twitter (TWTR) could be rethinking its news feed, potentially ordering posts based on popularity rather than chronological date. 4. Apollo Education (APOL) received a second investigative subpoena from California's attorney general related to the marketing, recruiting, accreditation, and other aspects of its for-profit schools. 5. Celgene (CELG), Gilead (GILD), Thermo Fisher (TMO) and Vantiv (VNTV) were mentioned positively by Barron's this weekend, while Church & Dwight (CHD) was called overvalued and GoPro was identified as a possible takeover target by Under Armour (UA) or Sony (SNE).
12:38 EDTCELGCelgene, Gilead too cheap to ignore, could rise 30% in next year, Barron's says
Shares of Celgene (CELG) and Gilead (GILD) could advance 30% over the next year, Barron's contends in a feature article. Concerns over the two firms having too much revenue concentrated in just a few key products are legitimate but "solvable," and their shares now look "too cheap to ignore" amid the general rout in biotech names, the publication says. Reference Link
February 5, 2016
09:26 EDTCELGLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:04 EDTCELGCelgene resumed with a Market Perform at Leerink
Subscribe for More Information
February 4, 2016
16:37 EDTCELGCelgene reinitiated with a Market Perform at Leerink
Subscribe for More Information
10:36 EDTCELGCelgene February weekly calls activity attributed to takeover speculation
Subscribe for More Information
10:31 EDTCELGRumor: Celgene strength attributed to takeover speculation
Shares of Celgene (CELG) are moving higher amid renewed speculation Bristol-Meyers (BMY) is interested in acquiring the company.
February 3, 2016
08:57 EDTCELGPullback in biotech makes M&A more attractive, says UBS
UBS analyst Andrew Peters noted the pullback in small and mid-cap biotechs and said a consequence of the lower valuations may be an increased appetite for M&A by the larger firms. Peters noted Gilead (GILD) commented on its earnings call that "there's no question" the pullback has made M&A more attractive. UBS said with valuations so far off their highs, the question remains whether management and boards will accept deals at such depressed levels.
February 2, 2016
08:53 EDTCELGPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
January 29, 2016
08:17 EDTCELGCelgene fundamentals, valuation compelling, says Cantor
Cantor says that Celgene's sell-off was not caused by its results, but by other factors such as currency fluctuations. The firm says that the company's EPs growth remains strong, while its pipeline can enable the company to keep growing over the longer term. The firm continues to expect the company to generate strong cash flow, and it reiterates a $163 price target and Buy rating on the shares.
08:06 EDTCELGUBS said no change to bullish stance on Celgene
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use